USPTO serial 88045390
CBIS
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- —
- Examiner
- TRUSILO, KELLY JEAN
- Law office
- TMEG LAW OFFICE 107 - EXAMINING ATTORNEY ASSIGNED
What this means
These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances. If abandonment was unintentional, consult counsel about a petition to revive. Otherwise file a new application if protection is still needed.
Need help with CBIS?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Faiyaz Dean
Faiyaz Dean DEAN LAW CORPORATION701 5TH AVENUE, SUITE 4200SEATTLE, WA 98104UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical preparations for the prevention and treatment of disorders of the nervous system, the immune system, the cardio-vascular system, the metabolic system, the respiratory system, the musculo-skeletal system, the genitourinary system; Pharmaceutical preparations for the treatment of inflammatory disorders; Pharmaceutical preparations for use in dermatology, oncology, hematology and in tissue and organ transplantation, in ophthalmology and for gastroenterological disorders; Drug delivery agents that provide controlled release of the active ingredients for a wide variety of cannabinoid pharmaceuticals; Pharmaceutical agents affecting peripheral nervous system; Pharmaceutical preparations for peripheral nervous system; Pharmaceutical agents affecting digestive organs; Pharmaceutical preparations for use in chemotherapy; Pharmaceutical products for the prevention and treatment of cancer; Therapeutic pharmaceutical for the treatment and prevention of inflammatory bowel disease; Pharmaceutical preparations for use in gastroenterology; Pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; Therapeutic pharmaceutical for the treatment and prevention of neurodegenerative disease; Therapeutic pharmaceutical for the treatment and prevention of neurological disorders; Pharmaceutical preparations for use in neurology; Pharmaceutical preparations and substances for the treatment and prevention of psychiatric diseases and disorders; Therapeutic pharmaceutical for the treatment and prevention of autoimmune conditions; Therapeutic pharmaceutical for the treatment and prevention of inflammation; Pharmaceutical preparations for the treatment and prevention of immune system related diseases and disorders; Therapeutic pharmaceutical for the treatment and prevention of pain; Pharmaceutical products for the treatment of viral and infectious diseases, for the treatment of cancer; Pharmaceutical preparations, namely, an analgesic for human consumption taken orally; Therapeutic pharmaceutical for the treatment of infections; Therapeutic pharmaceutical for the treatment of drug-resistant infections; Pharmaceutical preparations for the treatment of infectious diseases; Pharmaceutical agents affecting sensory organs; Analgesic and muscle relaxant pharmaceutical preparations; Pharmaceutical preparations for use in urology; Pharmaceutical products and preparations to prevent swelling in the legs; Pharmaceutical preparations for use in dermatology; Pharmaceutical preparations for use in opthalmology; Pharmaceutical preparations for treating skin disorders; Pharmaceutical preparations for ocular or intraocular surgery; Pharmaceutical preparations for treating chemical imbalances; Pharmaceutical products for treating respiratory diseases; Pharmaceutical preparations for skin care; Drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; Drug delivery agents in the form of powders that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; Pharmaceutical products for the treatment of viral and infectious diseases, for the treatment of cancer; Pharmaceutical preparations, namely, a drug delivery system comprising polymer-based oral tablets for the continuous release of a wide variety of therapeutic agents; Drug delivery agents in the form of tablets that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; Drug delivery agents in the form of capsules that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Pharmaceutical preparations for the prevention and treatment of ocular disorders or diseases, for the treatment of bacteria-based diseases, and for the treatment of diabetes, and anti - infective preparations, antiviral preparations, antibiotics, antifungal preparations and vaccines; Ocular pharmaceuticals; Antibacterial pharmaceuticals; Pharmaceuticals, namely, anti-infectives | ACTIVE | May 7, 2009 |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Aug 25, 2020 | MAB2 | ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| Aug 25, 2020 | ABN2 | ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| Feb 12, 2020 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Feb 12, 2020 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Feb 12, 2020 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jan 14, 2020 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jan 14, 2020 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jan 14, 2020 | ALIE | ASSIGNED TO LIE | — |
| Dec 24, 2019 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jun 25, 2019 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 25, 2019 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 25, 2019 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 20, 2019 | DOCK | ASSIGNED TO EXAMINER | — |
| Aug 7, 2018 | DOCK | ASSIGNED TO EXAMINER | — |
| Jul 27, 2018 | MDSC | NOTICE OF DESIGN SEARCH CODE E-MAILED | — |
| Jul 26, 2018 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |